Risk Assessment and Treat Compliance in Hypertension Education Trial (RATCHET)

This study has been completed.
University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
First received: June 6, 2008
Last updated: June 29, 2011
Last verified: June 2011
The RATCHET study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertension.

Condition Intervention
Behavioral: Knowledge of Cardiovascular Risk Assessment

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension

Resource links provided by NLM:

Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Medication Compliance [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient perception of cardiovascular risk [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Pilot Feasibility Study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Blood Pressure [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Cholesterol Level [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Framingham Risk Score (stroke and coronary artery disease) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: May 2007
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: B
Standard Care
Experimental: A
Risk Assessment plus standard care
Behavioral: Knowledge of Cardiovascular Risk Assessment
Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.


Ages Eligible for Study:   30 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Essential hypertension (new diagnosis or established diagnosis) meeting criteria for pharmacologic therapy as defined by current guidelines

Exclusion Criteria:

  • Lack of written informed consent
  • Previous myocardial infarction
  • Previous stroke
  • Congestive heart failure
  • Stage 3 or greater chronic kidney disease
  • Pregnancy
  • Usage of medication bubble/blister package
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00694239

Canada, Ontario
University of Western Ontario
London, Ontario, Canada, N6A 5A5
Sponsors and Collaborators
Lawson Health Research Institute
University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation
Principal Investigator: Bryan J Har, MD University of Western Ontario, Canada
Principal Investigator: George K Dresser, PhD, MD University of Western Ontario, Canada
  More Information

Additional Information:
Responsible Party: George Dresser, University of Western Ontario
ClinicalTrials.gov Identifier: NCT00694239     History of Changes
Other Study ID Numbers: R-07-053  13014E 
Study First Received: June 6, 2008
Last Updated: June 29, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by Lawson Health Research Institute:

Additional relevant MeSH terms:
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 23, 2016